Get started
Author

Julia Strauß

Observed names: J Strauss, Julia Strauss, Strauss, Julia
ORCID: 0009-0008-7016-8817
Observed ORCID: 0009-0008-7016-8817
OpenAlex ID: A5089507510
Familial Hemophagocytic Lymphohistiocytosis Type 5 (FHL-5) Is Caused by Mutations in Munc18-2 and Impaired Binding to Syntaxin 11
2009 · Udo zur Stadt, Jan Rohr, et al. · The American Journal of Human Genetics · 424
PDF
Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling
2012 · Helena Brauer, Julia Strauss, et al. · Cellular Signalling · 34
Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair
2019 · Marcos Seoane, Sophia Buhs, et al. · Oncogene · 28
PDF
Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL
2018 · Ina-Katrin Siekmann, Kevin Dierck, et al. · Blood Advances · 22
Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al. · Cancer Immunology Research · 1
A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal GCC2::PDGFRB t(2;5) translocation – implementation for the selection of MRD-targets
2025 · Esther L. Monsees, Richard T. Hauch, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
Characterization of a PRKCE::ETV6 fusion as a potential oncogenic driver in T-cell acute lymphoblastic leukemia
2025 · Esther L. Monsees, Udo zur Stadt, et al. · Molecular and Cellular Pediatrics
PDF
Data from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S12 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S11 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S1 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S4 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S3 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S5 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S6 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S9 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Table S2 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Table S3 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Table S1 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S8 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S7 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S2 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S10 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Memory-like NK cell and CD19-antibody based immunotherapy combined with TKI has antitumor effects against Ph(-like) ALL
2025 · A Lane, N Kleist, et al. · Klinische Pädiatrie
FOXM1 haploinsufficiency in acute lymphoblastic leukemia
2017 · S Raasch, A Bronsema, et al. · Klinische Pädiatrie
Works count: 30
Citation count: 510
H-index: 4
I10-index: 4
Year
Topic
Type